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Abstract Deletion of chromosome 13q14 is the most frequent
genetic aberration in B-cell chronic lymphocytic leukemia
(CLL), found in more than 50% of cases, indicating that this
region contains a gene(s) involved in the development of CLL.
However, the pathogenic gene in the critical 13q14 region has
not yet been de¢ned. Here, we have cloned and characterized a
novel gene, DLEU7, located adjacent to the consensus deleted
region, and overlapping the 3P end of DLEU1 tail to tail. Hu-
man DLEU7 encodes a putative 221 amino acid protein, with
signi¢cant conservation in rodents. Mutational and expression
analysis in primary CLL samples failed to demonstrate any
speci¢c mutations in DLEU7, but no DLEU7 expression could
be detected in CLL cells. Methylation of a CpG island in the
promoter region of DLEU7 was further analyzed as a possible
mechanism for the absence of DLEU7 expression, and the pro-
moter was found to be methylated in the majority of the CLL
samples investigated.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most
frequent leukemia in the Western world [1]. The molecular
pathogenesis of this disease has remained largely unknown,
but previous studies have indicated the presence of a putative
tumor suppressor gene on chromosome 13q14, a region de-
leted heterozygously in 30^60% and homozygously in 10^20%
of CLL patients [2^7]. Recently it has become apparent that
loss of the same region of 13q is frequent not only in other
hematological malignancies such as myeloma [8,9], mantle cell
lymphoma [10], di¡use large cell lymphoma [11], and myelo-
¢brosis [12], but also in solid tumors including head and neck
tumors [13], oral tumors [14] and prostate carcinoma [15].
Surprisingly, no speci¢c inactivating mutations have been
found in any gene mapped to the region. There is, however,
some discrepancy concerning the location of the critical 13q
deleted region (CDR), with some studies suggesting a slightly
more telomeric area being important [3,16]. The lack of mu-
tations of candidate genes, despite the high instances of ge-
nomic loss, suggests that the pathomechanism involving
13q14 may involve haploinsu⁄ciency or is of an epigenetic
nature. Epigenetic silencing of tumor suppressor genes by hy-
permethylation has been detected in a variety of malignancies
[17,18]. However, no aberrant promoter methylation pattern
could be demonstrated in the genes located in the consensus
13q14 CDR, DLEU1, DLEU2 and RFP2/LEU5 [19].
In the present study we have cloned and characterized a
novel gene, DLEU7, located adjacent to the critical 13q14
CLL deletion region and with overlapping 3P ends with
DLEU1. We have analyzed the deletion status of DLEU7
and performed mutation screening of the gene on leukemic
DNA from a number of B-CLL patients. The methylation
pattern of the DLEU7 promoter has been investigated in B-
CLL patient material, in addition to the expression status of
the gene.
2. Materials and methods
2.1. Computer programs
Genomic DNA sequences were obtained from the Human and
Mouse assemblies available through the UCSC genome browser
home page (http://genome.ucsc.edu/). These sequences were aligned
using the needle program of the EMBOSS package [20], and analyzed
for the presence of conserved transcription factor binding sites using
the web resource ConSite (http://www.phylofoot.org/consite/) [21].
Putative transcription start points were predicted by the computer
program Eponine (http://www.sanger.ac.uk/Software/analysis/epo-
nine/). The NCBI site (http://www.ncbi.nlm.nih.gov/) was used for
BLAST homology searches and peptide sequence retrieval. Sequence
alignments were performed with the ClustalW program [22].
2.2. Polymerase chain reaction (PCR), rapid ampli¢cation of cDNA
ends (RACE), real-time PCR and single-stranded conformational
polymorphism (SSCP)
RT-PCR was performed as described previously [23] on a cDNA
panel of human tissues (Clontech) and on cDNA from CLL patient
samples that had been £ow sorted to s 99% purity on the basis of
CD19 and CD5 positivity. All basic molecular biology procedures
(isolation of DNA, growing of bacteria, cloning etc.) were performed
according to standard procedures [24]. Primers used for ampli¢cation
of the DLEU7 gene are shown in Table 1. 3P RACE-PCR analysis was
carried out as previously described [23] on cDNAs from various hu-
man tissues as template. Di¡erentially spliced 3P RACE products were
subcloned using the TOPA-TA cloning kit (pCR.2.1; Invitrogen) and
sequenced.
RNA was extracted from CD19+ puri¢ed B-cells of healthy donors
(CD19 Dynabeads, Dynal Biotech, Norway) with Trizol Reagent
(Life Technologies). The RNA was reverse transcribed with First-
Strand cDNA synthesis using Superscript II (Invitrogen, Life Tech-
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nologies). Real-time PCR was carried out in an Bio-Rad iCycler by
using the SYBR green PCR kit (Bio-Rad Laboratories, Hercules, CA,
USA). Primer sequences for DLEU7 and L2-microglobulin (B2M)
used as control are shown in Table 1.
The primers used for SSCP analysis are listed in Table 1. For SSCP,
the resulting PCR products were further digested by AluI prior to the
analysis by polyacrylamide gel electrophoresis as previously described
[25].
2.3. Northern analysis
Total RNA was isolated using Trizol reagent according to the
manufacturer’s protocol (Life Technologies). 20 Wg total RNA was
separated on a 1% agarose formaldehyde gel and blotted onto Zeta-
Probe membranes (Amersham). All Northern blots were hybridized
with PCR-derived probes for the coding region of DLEU7, according
to the manufacturer’s recommendations (MTN blots, Clontech). La-
beling of all probes was performed as previously described [23].
2.4. Bisul¢te treatment and sequencing
A DNA sample of 1 Wg was bisul¢te-modi¢ed according to stan-
dard protocols of Issa and Frommer (http://www3.mdanderson.org/
leukemia/methylation/protocols.html). 50 ng of each sample was sub-
sequently used in each methylation-speci¢c PCR reaction. Primers
Methyl-F1 plus Methyl-R1 and nested primers Methyl-F2 plus Meth-
yl-R2 were used to amplify a 190 bp fragment from the bisul¢te-
treated DNA samples. Restriction digestion of the resulting products
and size fractionation on 2% agarose gels allowed the determination
of the methylation status of DLEU7. Methylated samples were iden-
ti¢ed by the presence of the restriction enzyme sites TaqI or HhaI that
were absent in unmethylated fragments. Some PCR products were
further analyzed by bi-directional sequencing, as previously described
[26].
3. Results
3.1. Cloning and de¢nition of the genomic structure of a novel
B-CLL candidate gene ^ DLEU7
Our group previously analyzed 1.3 Mb of genomic sequence
covering the commonly deleted 13q14 region in CLL (unpub-
lished data) and identi¢ed an EST, termed DLEU7, located
150 kb telomeric to the marker D13S25. In the present inves-
tigation, the full length DLEU7 was isolated by RT-PCR on a
mixture of normal cDNAs, using primers designed from sur-
rounding ESTs putatively associated with DLEU7 (Table 1).
This revealed that DLEU7 is alternatively spliced, extends
over 130 kb of genomic sequence and is composed of at least
six exons (Fig. 1). All intron^exon junctions matched the con-
sensus AG and GT nucleotides at the intron acceptor and
donor sites, respectively. In mouse several homologous ESTs
from the syntenous region were found that extend further 5P
as compared to the ESTs in human. By RT-PCR, combining
primers located in the corresponding human genomic se-
quence with primers located in downstream exons, followed
by sequencing of the PCR products, the existence of a longer
5P end of DLEU7 also in human was con¢rmed.
An in silico analysis of the region covering the ¢rst exon
and the 1 kb upstream sequence revealed the existence of a
CpG island covering the ¢rst exon, a putative transcription
start site with high probability (threshold of 0.99) as well as
the presence of binding sites for several transcriptions factors,
such as basic helix-loop-helix transcription factors that bind
to E-box motifs (Myf, Tal1 and Myc-Max) and others in-
volved in cell proliferation and di¡erentiation (AML-1, E2F
and cFOS (bZIP)) (Fig. 2). All of the above-mentioned tran-
scription factor binding sites are conserved in mouse (Fig. 2),
increasing the likelihood that these elements are involved in
transcriptional regulation of DLEU7.
The DLEU7 cDNA found to date is 1137 bp, with a 5P
untranslated region (UTR) of 65 bp and an in-frame ¢rst
ATG codon within a Kozak context for ribosome binding
[27]. A putative open reading frame (ORF) of 663 bp extends
Table 1
Primer sequences
Primer name Sequence 5PC3P
Ex1F2 CAGGTGAATGGGAAAGGACCGCTC
Ex1F1 CTGCACGCCAGAGGGGATGGC
Ex1R1 GCGGGTTAGAAAATGTGAC
Ex1R2 CGCTGCTGCTCCACCTGCAC
Ex1R3 CGGAGCTGGTCAGCGTGGAGC
Ex1R4 GCAGGAGCGGTCCTTTCCCATTCAC
Ex2F1 GCCACTGGTCAGACTGCTCCAC
Ex2R1 CCAGAGTGCTGTCACCAGAAGAGA
Ex2R2 CCTTCCTAATTGAGTCAGCAGAC
Ex2R3 GGAGCAGTCTGACCAGTGGCATC
Ex5F1 GCCAGCAGGTGAGAAGCTAGAC
Ex5F2 GACAGAGCAGCCGGTGGCAGC
Ex6F1 GCTCCTGATGGTCCTCACACTCC
Ex6F2 CTACAGTGACCTTCTTCACTCATTAGC
Ex6R1 CTGGCTAATGAGTGAAGAAGG
Ex6R2 GAGTGTGAGGACCATCAGGAGCTTCA
Methyl-F1 TTGGAGGATGGGAGGTTATTTTGTA
Methyl-F2 TTGTTGGAGGGGTTTTAGTA
Methyl-R1 AACTCTACAAACCTTACAACTACTACAAC
Methyl-R2 AACTCCCCAAAAAAAAAAATAATAC
RT-LEU7F GATCTGTCTCAAGGAAGCACA
RT-LEU7R TCCCATTCACCTGAAGGATAG
RT-B2MF CAAGCAGAGAATGGAAAGTC
RT-B2MR GATGCTGCTTACATGTCTCG
Fig. 1. The genomic structure of the DLEU7 gene and its relation to DLEU1. The individual exons for DLEU7 and DLEU1 are marked as
black and gray boxes, respectively. The putative DLEU7 ORF is shown as dashed boxes. Polyadenylation signals are denoted as pA. The direc-
tions of transcription are indicated by the arrows. ‘Cen’ and ‘Tel’ show the positions of the centromere and telomere, respectively.
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from exon 1 to exon 2 with the possibility to encode a 221
amino acid protein (Fig. 3). To identify the 3P end of the
DLEU7 cDNA, 3P RACE was carried out, revealing that
the DLEU7 3P UTR can have at least three alternative
lengths. Putative polyadenylation signals (ATTAAA) could
be identi¢ed in two of the 3P ends, 15^18 bp upstream of
the poly(A) tail, resulting in one 3P UTR region of 409 bp
and one 3P UTR of 690 bp. The DLEU7 cDNA sequence
has been submitted to GenBank under accession number
AY357595. Interestingly, DLEU7 was found to be located
tail to tail with DLEU1, with exons 4, 5 and 6 of DLEU7
located within intron 44 of DLEU1 (Fig. 1).
3.2. DLEU7 encodes an evolutionarily conserved protein
The predicted coding sequence for the dleu7 protein (sub-
mitted to GenBank under accession number AY357595) was
used to search the GenBank/EMBL protein sequence data-
bases for homologous sequences. Highly conserved dleu7 pro-
Fig. 2. Conservation within the promoter region of DLEU7 between human and mouse. Nucleotide 1 is located 613 bp upstream of the puta-
tive transcriptional start site (TSS). The yellow area corresponds to exon 1. Potential conserved transcription factor binding sites are indicated.
(For interpretation of the references to color in this ¢gure legend, the reader is referred to the web version of this article.)
Fig. 3. The dleu7 protein is conserved between human, rat and mouse. A ClustalW alignment of the human dleu7 protein and orthologs from
mouse and rat. Columns colored black highlight identical amino acids between the proteins, whereas shaded and white boxes represent conser-
vative and non-conservative amino acid substitutions respectively. The % identity and similarity between the dleu7 in human, mouse and rat
are: human^mouse: 82.8% and 86%; human^rat: 83.7% and 86.0%; mouse^rat: 97.1% and 98.1%, respectively.
FEBS 27929 19-12-03 Cyaan Magenta Geel Zwart
M. Hammarsund et al./FEBS Letters 556 (2004) 75^80 77
teins were found in both mouse and rat (GenBank accession
numbers XP_214218 and NP_775595, respectively) (Fig. 3).
The dleu7 protein was not found to contain any known func-
tional domains.
3.3. Genomic status of the DLEU7 gene in B-CLL
To investigate genomic abnormalities of the DLEU7 gene in
CLL cells, Southern blot analysis was performed on leukemic
cell DNA from CLL patients with a cDNA probe covering
the coding part of the gene. These leukemic samples have been
analyzed in previous investigations with probes covering the
CDR [4], including a probe for the adjacent marker D13S25
located only 40 kb centromeric of DLEU7. Consistent with
previous studies, the DLEU7 region clearly is less frequently
deleted (51/152 (34%) deleted) compared to our previously
de¢ned CDR (93/229 (41%) deleted).
3.4. DLEU7 is not mutated in B-CLL
In an e¡ort to identify possible point mutations or small
nucleotide sequence aberrations in the DLEU7 gene, PCR-
based SSCP analysis was performed across the protein-encod-
ing part of the DLEU7 gene (exon 1 and exon 2) on DNA
from 45 B-CLL patients. Out of these samples, 24 were pre-
viously found to have hemizygous loss of the CDR at 13q14
and 21 samples had no detectable deletion of 13q14. No alter-
ations were, however, found in any of the patient samples
analyzed (data not shown).
3.5. Expression analysis of the DLEU7 gene in normal tissues
and B-CLL cells
Poly(A)þ RNA from various normal human tissues (Clon-
tech) was hybridized with a cDNA probe covering the coding
region of the DLEU7 gene. Five transcripts of 1 kb, 3 kb, 5.5
kb, 8 kb and 10 kb could be detected (Fig. 4). The four larger
transcripts were found to be ubiquitously expressed at various
levels in all human tissues tested, whereas the 1 kb transcript
could only be detected in placenta (Fig. 4).
DLEU7 expression was further analyzed in total RNA iso-
lated from puri¢ed mononuclear cells from B-CLL patients,
consisting of s 95% leukemic cells. Samples from nine CLL
patients with either homozygous, hemizygous deletions or no
13q deletions as well as two CLL cell lines with homozygous
13q deletions were included in the analysis. None of the
DLEU7 transcripts could be detected in any of the CLL sam-
ples analyzed (data not shown).
Expression of DLEU7 was also analyzed by real-time PCR
using cDNA derived from puri¢ed CD19+ B-cells from
healthy donors, as well as various tissues such as fetal liver,
kidney and brain. None of the CD19+ B-cell samples showed
detectable levels of DLEU7 in contrast to the other tissues
analyzed, where DLEU7 expression could clearly be detected.
3.6. The DLEU7 promoter is methylated in B-CLL cells
The lack of DLEU7 expression, despite the presence of un-
mutated DLEU7 alleles in B-CLL cells, could be due to epi-
genetic changes, such as methylation. To test this hypothesis
the promoter region of DLEU7 was analyzed for methylation
in CLL cells.
Sequence analysis of bisul¢te-modi¢ed DNA from six puri-
¢ed CLL cases within the DLEU7 5P genomic region allowed
us to determine that the CpG dinucleotides most frequently
methylated in these samples occurred at the sites of TaqI or
HhaI restriction enzymes. These restriction enzymes, which
contain CpG dinucleotides within their cutting sites, will
thus only cut methylated samples that have retained these
dinucleotides following bisul¢te treatment. A total of 157 pu-
ri¢ed CLL cell DNA samples were then analyzed by PCR
ampli¢cation using bisul¢te-speci¢c DLEU7 primers (Table
Fig. 4. DLEU7 expression in various human tissues. Northern blots, containing mRNA from various human tissues, were hybridized with a
cDNA probe covering the DLEU7 coding sequence. The positions of the DLEU7 transcripts are indicated by the arrows. Hybridization with a
L-actin control probe was performed to con¢rm equal loading (not shown).
Fig. 5. Analysis of the methylation status of the DLEU7 promoter
in leukemic DNA from CLL patients. U (uncut) shows a PCR frag-
ment of the DLEU7 promoter prior to digestion with restriction en-
zyme (HhaI). C (cut) shows the same PCR fragment following di-
gestion with restriction enzyme. Sample 1 could not be cut by HhaI,
indicating an unmethylated status of the DLEU7 promoter. Sample
2 is digested by HhaI indicating a methylated status of the promoter
and sample 3 is partially cleaved by HhaI indicating a partial meth-
ylation of the promoter.
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1) and restriction enzyme digestion. Of these samples the ma-
jority, 61% (95/157), resulted in the digestion of the majority
of the PCR product with either TaqI or HhaI, indicating the
presence of methylated CpG dinucleotides within the target
sequence (Fig. 5 and Table 2). Approximately 25% (40/157) of
the samples did not cut following TaqI or HhaI digestion,
indicating that the region was not methylated in these cases,
while the remaining 14% (22/157) of cases resulted in aV50%
digestion of the PCR product, possibly showing evidence of
partial methylation of this region or that DLEU7 methylation
did not occur throughout every cell in the puri¢ed sample
(Fig. 5 and Table 2). There was no signi¢cant di¡erence be-
tween the methylation in heterozygous 13q deleted compared
to non-13q deletion CLL cases.
Methylation analysis of samples from another B-cell malig-
nancy with frequent 13q deletions was also carried out, with
25 cases of mantle cell lymphoma showing methylation in 30%
(8/25) of the cases and 20% (5/25) being unmethylated at this
locus. The remaining 12 samples (45%) gave a mixed pattern.
Interestingly, two B-cell samples puri¢ed by £ow sorting
from healthy donors gave di¡ering results compared to the
CLL samples. One sample (CD5+ CD273) showed evidence
of hypomethylation while another sample containing just
CD19+ sorted B-cells showed a mixed methylation result. A
sample derived from a pre-B-acute lymphocytic leukemia case
on the other hand was methylated at this locus. Nine B-cell
malignancy-derived cell lines, mainly lymphoma-derived cell
lines, including NCEB-1, Karpas231 and WI33, were also
screened for DLEU7 methylation, all which were found to
be methylated at this locus.
4. Discussion
The high frequency of both heterozygous and homozygous
loss of chromosome 13q14 in B-CLL patients strongly indi-
cates that this region contains a gene(s) involved in the devel-
opment of this malignancy [7]. None of the three genes
DLEU1, DLEU2 and RFP2/LEU5 located in the consensus
CDR at 13q14 have, however, been found mutated or meth-
ylated in hemizygous loss CLL cases, which would ¢t with the
classical two-hit model for tumor suppressor genes [23,28,29].
The absence of somatic mutations was also described for a
series of centromerically located genes, CLLD6, CLLD7 and
CLLD8 [30]. These results either indicate that the classical
tumor suppressor mechanism involving hemizygous deletion
and mutation of the remaining allele may not underlie the
alterations found at this locus, or may simply re£ect the
fact that the true pathogenic gene at 13q14 has not yet been
identi¢ed. Some studies pointing towards a slightly more dis-
tal region in B-CLL [3,16] indicate that an adjacent telomeric
gene could be of importance.
In the present study we have cloned and characterized a
novel candidate gene, DLEU7, located just outside the con-
sensus deleted CLL region. The DLEU7 gene is transcribed in
a telomeric to centromeric direction with its 3P end overlap-
ping the 3P end of the DLEU1 gene, which is located within
the minimal deleted region at 13q14. Both DLEU1 and the
centromeric DLEU2 lack any convincing ORF, and these
genes have been proposed to act at the RNA rather than
the protein level. Indeed, we have recently shown that the
DLEU2 transcript (GenBank accession number AY455757)
can act as an antisense for the adjacent bicistronic protein
encoding LEU5/RFP2 gene (GenBank accession number
AY455758) (unpublished data). The fact that DLEU1 and
DLEU7 have overlapping 3P ends may indicate that these
genes could be functionally related as well, although no di-
rectly overlapping exons could be demonstrated.
Northern blot analysis has shown that DLEU7 is alterna-
tively spliced with ¢ve major transcripts. The larger tran-
scripts indicate the possibility that additional exons exist,
not yet cloned. These exons might be located towards the
CDR, since it is known that a longer 3P UTR is the most
common reason for signi¢cantly larger isoforms [31].
DLEU7 was found to have the capability to encode a 221
amino acid protein, with high conservation in mouse and
rat (Fig. 3). The dleu7 protein does not contain any known
functional domains that could indicate a possible function of
the protein. However, small portions of an ATPase domain
and a CRM1 L-importin domain were identi¢ed. The func-
tional signi¢cance of the partial motifs is unclear, but dleu7
may function as a nuclear protein.
To investigate the role of this novel candidate gene in B-
CLL, the mutational and the expression status was examined.
However, no speci¢c alterations were discovered in any tumor
sample. Despite ubiquitous DLEU7 expression in human tis-
sues, DLEU7 was not detectably expressed in any of the CLL
patient samples analyzed, regardless of the presence or ab-
sence of chromosome 13q14 deletions. Since the exact normal
counterpart of B-CLL is unclear [1], it is di⁄cult to address if
the lack of expression of DLEU7 in B-CLL cells just re£ects
the lack of transcription of this gene in the normal counter-
part of B-CLL. The expression level of DLEU7 has however
been analyzed in CD19+ B-cells puri¢ed from healthy donors.
These cells did not show any detectable expression of DLEU7.
The lack of DLEU7 expression in CLL cells could be associ-
ated with this ¢nding. Further studies should aim at analyzing
the transcription status of DLEU7 in cells that might be the
normal counterpart of B-CLL cells, such as normal naive or
memory B-lymphocytes.
The hypermethylation of promoter regions of tumor sup-
pressor genes is a frequent ¢nding and has often been found
to be associated with transcriptional non-expression of these
genes. For example, CpG island methylation has been de-
scribed for RB1, VHL, BRCA1, E-cadherin, p15INK4A and
p73 [18,32]. In the case of DLEU7, the gene contains a clear
CpG island overlapping exon 1. The conservation of this re-
gion in mouse and rat is signi¢cant (Fig. 1), strengthening the
notion that this area functions as a true promoter for the
DLEU7 gene. We found that this region was hypermethylated
or showed a mixed methylation pattern in 75% of cases (Fig. 5
and Table 2), a ¢nding consistent with the lack of DLEU7
expression seen in the CLL cases tested. Methylation at CpG
islands tends to be a stochastic process and occurs in silenced
chromatin. Partial methylation is also frequently seen, since
Table 2
Methylation status of the DLEU7 promoter in primary CLL sam-
ples
Methylation status of the DLEU7 promoter CLL patients (%)
Methylated 95 (61)
Partial methylation 22 (14)
Unmethylated 40 (25)
Total number of CLL patients 157
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individual sites have a variable probability of methylation
within an overall methylated CpG island [33]. Although our
methylation-speci¢c analysis was based on initial studies eval-
uating the frequently methylated nucleotides across the
DLEU7 promoter by sequencing of bisul¢te-treated DNA,
the ¢nal analysis of a large set of CLL patients only re£ects
the methylation status at certain residues in the CpG island
analyzed. It is possible that samples showing lack of methyl-
ation-speci¢c digestion might be methylated at other sites not
analyzed in detail in the larger set of CLL patients. Alterna-
tively, the lack of expression of DLEU7 also seen in cases
where no promoter methylation could be detected may be
correlated with histone modi¢cations rather than changes at
the DNA level. Future studies determining the histone status
of this region could thus be of interest.
It is interesting to note that conserved binding sites for a
number of transcription factors can be found in the DLEU7
promoter, several of which have obvious roles in cell prolif-
eration and di¡erentiation as well as tissue-speci¢c expression
of genes. It is also notable that conserved binding sites exist
for transcription factors whose regulation is altered in hema-
tological malignancies, such as Tal1 and AML-1 [34,35]. It is
thus conceivable that DLEU7 regulation may be altered in
these malignancies.
In summary, the present investigation describes the cloning
and characterization of a novel conserved protein-encoding
gene in the 13q14 deletion region. This candidate gene was
found not to be expressed in primary CLL cells, which were
also frequently found to have a hypermethylated DLEU7 pro-
moter. These studies form a basis for the further evaluation of
the role of DLEU7 in B-CLL and other malignancies.
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